Skip to main content
Duke University Libraries
Search 
  •   DukeSpace
  • Duke Scholarly Works
  • Search
  •   DukeSpace
  • Duke Scholarly Works
  • Search
    • Login
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Search

    Show Advanced FiltersHide Advanced Filters

    Filters

    Use filters to refine the search results.

    Now showing items 1-3 of 3

    • Sort Options:
    • Relevance
    • Title Asc
    • Title Desc
    • Issue Date Asc
    • Issue Date Desc
    • Results Per Page:
    • 5
    • 10
    • 20
    • 40
    • 60
    • 80
    • 100
    Thumbnail

    Provider specialty and atrial fibrillation treatment strategies in United States community practice: findings from the ORBIT-AF registry. 

    Fosbøl, Emil; Gersh, Bernard John; Holmes, DaJuanicia; Kowey, Peter R; Mahaffey, Kenneth William; Mills, RM; ORBIT-AF Investigators and Patients; ... (11 authors) (J Am Heart Assoc, 2013-07-18)
    BACKGROUND: The prevalence of atrial fibrillation (AF) continues to increase; however, there are limited data describing the division of care among practitioners in the community and whether care differs depending on provider ...
    Thumbnail

    Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. 

    Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, Bernard John; Holmes, DaJuanicia; Hylek, EM; ... (15 authors) (J Am Heart Assoc, 2013-11-25)
    BACKGROUND: Dabigatran is a novel oral anticoagulant approved for thromboprophylaxis in atrial fibrillation. Adoption patterns of this new agent in community practice are unknown. METHODS AND RESULTS: We studied patterns ...
    Thumbnail

    The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. 

    Ansell, JE; Chang, P; Fonarow, GC; Gersh, Bernard John; Hylek, EM; Kowey, Peter R; Mahaffey, Kenneth William; ... (13 authors) (Eur Heart J, 2015-12-07)
    BACKGROUND: Therapeutic decisions in atrial fibrillation (AF) are often influenced by assessment of bleeding risk. However, existing bleeding risk scores have limitations. OBJECTIVES: We sought to develop and validate a ...
     

     

    Browse

    All of DukeSpaceCommunities & CollectionsAuthorsTitlesTypesBy Issue DateDepartmentsAffiliations of Duke Author(s)SubjectsBy Submit DateThis CommunityAuthorsTitlesTypesBy Issue DateDepartmentsAffiliations of Duke Author(s)SubjectsBy Submit Date

    My Account

    LoginRegister

    Discover

    AuthorGersh, Bernard John (3)
    Kowey, Peter R (3)
    Mahaffey, Kenneth William (3)
    Peterson, Eric David (3)
    Piccini, Jonathan Paul Sr (3)Thomas, Laine Elliott (3)Chang, P (2)Fonarow, GC (2)Holmes, DaJuanicia (2)Hylek, EM (2)... View MoreDate Issued2013 (2)2015 (1)TypeJournal article (3)SubjectAged (3)Aged, 80 and over (3)Anticoagulants (3)Atrial Fibrillation (3)Female (3)Humans (3)Male (3)
    Middle Aged (3)
    Registries (3)atrial fibrillation (2)... View MoreAffiliation of Duke Author(s)
    Basic Science Departments (3)
    Biostatistics & Bioinformatics (3)Clinical Science Departments (3)
    Duke (3)
    Duke Clinical Research Institute (3)Institutes and Centers (3)Medicine (3)Medicine, Cardiology (3)
    School of Medicine (3)
    Medicine, Clinical Pharmacology (1)